News

Alkem Laboratories Partners with Takeda Pharmaceutical to Launch Innovative Gastrointestinal Drug in India

• By Newsdesk
• New Delhi
• Sep 03, 2024

News

Alkem Laboratories announced on Monday a strategic patent licensing agreement with Japan's Takeda Pharmaceutical Company, paving the way for the commercialization of Vonoprazan in India. This innovative medication, available in 10 mg and 20 mg strengths, is primarily prescribed for the treatment of reflux esophagitis (RE), a chronic condition that causes inflammation of the esophagus due to acid reflux. Additionally, Vonoprazan is indicated for other gastrointestinal issues, including gastric and duodenal ulcers.

This partnership marks a significant milestone for Alkem Laboratories, a company with a robust presence in the gastrointestinal segment of the pharmaceutical industry. By securing a nonexclusive patent license from Takeda, Alkem aims to introduce a groundbreaking treatment option for millions of Indian patients suffering from gastro-related ailments. The drug's novel mechanism of action, which distinguishes it from existing treatments, has the potential to significantly improve patient outcomes in a country where digestive disorders are increasingly common.

In a statement, Alkem Laboratories CEO Vikas Gupta expressed optimism about the collaboration, highlighting the potential impact on patient care. "Our presence in the gastrointestinal segment is formidable, and this nonexclusive patent license with Takeda will enable us to offer a product with a novel mechanism of action to a large number of patients in India who are suffering from gastro-related ailments," Gupta stated.

As the company prepares to bring Vonoprazan to market, this collaboration is expected to not only enhance Alkem's product portfolio but also provide Indian patients with access to cutting-edge treatment options, addressing a critical need in the healthcare sector.